22/04/2004 (Agence Europe) - The European Commission has chosen the consulting company for assisting in the decision applied to life sciences and chemistry ALCIMED for carrying out a study on the issue of orphan medicine prices. This study aims to assess the system for determining medicine prices, as well as defining tools for evaluating if prices are reasonable, for the point of view of patients, business leaders and Member States. (Info: c.flin@hbcommunication.fr).